| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alberto Raggi, Alessandro Serretti, Raffaele Ferr. Treatment options for depression in Parkinson's disease: a mini-review. International clinical psychopharmacology. 2025-03-12. PMID:40071596. |
pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (ssris), serotonin and norepinephrine reuptake inhibitors (snris), levodopa, dopaminergic agonists, and monoamine oxidase b inhibitors. |
2025-03-12 |
2025-03-14 |
Not clear |
| Sanghoon Kim, Edward Pajarillo, Alexis Digman, Itunu Ajayi, Deok-Soo Son, Michael Aschner, Eunsook Le. Role of dopaminergic RE1-silencing transcription factor (REST) in manganese-induced behavioral deficits and dysregulating dopaminergic and serotonergic neurotransmission in mice. Neurotoxicology. 2025-03-08. PMID:40057281. |
neurotransmitters, including da, serotonin (5-ht), norepinephrine (ne), and glutamate, were analyzed in different brain regions, such as the striatum, midbrain, cortex, hippocampus, and cerebellum. |
2025-03-08 |
2025-03-12 |
mouse |
| Malaak Brubaker, Shivani Kapadia, Vladimir Maletic, Jessie S Chambers, Christopher P Watling, Leslie Citrom. Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review. Neuropsychiatric disease and treatment. vol 21. 2025-03-05. PMID:40041884. |
brexpiprazole, when administered with antidepressant therapy, may provide additional benefits due to complementary actions on noradrenaline (norepinephrine), serotonin, and dopamine neurotransmitter systems. |
2025-03-05 |
2025-03-07 |
Not clear |
| Natalia Łapińska, Jakub Szlęk, Adam Pacławski, Aleksander Mendy. Machine Learning Tool for New Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitors. Molecules (Basel, Switzerland). vol 30. issue 3. 2025-02-13. PMID:39942741. |
the aim of the study was to develop quantitative structure-activity relationship (qsar) models for serotonin (sert) and norepinephrine (net) transporters to predict the affinity and inhibition potential of new molecules. |
2025-02-13 |
2025-02-15 |
Not clear |
| Aila Malik, Zoe Brown, Alexa Ryder, Vanshika Balayan, Lauren Jameson, Peter Vu, Rana Al-Jumah, Jamal Hasoo. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) for Treatment of Fibromyalgia: A Comprehensive Clinical Review. Psychopharmacology bulletin. vol 55. issue 2. 2025-02-12. PMID:39935669. |
serotonin and norepinephrine reuptake inhibitors (snris) for treatment of fibromyalgia: a comprehensive clinical review. |
2025-02-12 |
2025-02-14 |
Not clear |
| Eduard Vieta, Nahida Ahmed, Celso Arango, Anthony J Cleare, Koen Demyttenaere, Markus Dold, Tetsuro Ito, Yerkebulan Kambarov, Stephanie Krüger, Pierre-Michel Llorca, Roger S McIntyre, Gabriele Sani, Christian von Holt, Benoit Riv. Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 93. 2025-02-09. PMID:39923271. |
escape‑trd (nct04338321) was a 32-week randomised, open‑label, rater‑blinded, active‑controlled phase iiib study comparing the efficacy and safety of esketamine ns versus quetiapine xr, both alongside an ongoing selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor (ssri/snri), in patients with trd. |
2025-02-09 |
2025-02-13 |
Not clear |
| Varsha L Kenkare, Bhushan Madke, Ankita Choudhary, Shiti Bos. Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers. Indian journal of dermatology. vol 70. issue 1. 2025-02-03. PMID:39896303. |
these include selective serotonin reuptake inhibitors like citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, alongside selective serotonin norepinephrine reuptake inhibitors such as venlafaxine, desvenlafaxine, and duloxetine. |
2025-02-03 |
2025-02-05 |
Not clear |
| Isabella Berardelli, Elena Rogante, Federico Formica, Riccardo Iannazzo, Attilio Valerio Mammoliti, Raffaele Riccioni, Skender Veizi, Roger S McIntyre, Maurizio Pompil. The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis. Journal of psychopharmacology (Oxford, England). 2025-02-01. PMID:39891526. |
among the available pharmacological treatments for acute major depressive disorder (mdd), vortioxetine, a serotonin transporter inhibitor (sert), has been widely used for its multimodal action on serotonin neurotransmission, which produces essential changes also on glutamate, gamma amino butyric acid (gaba), norepinephrine, acetylcholine, and dopamine. |
2025-02-01 |
2025-02-04 |
Not clear |
| Mandakh Bekhbat, Andrew M Block, Sarah Y Dickinson, Gregory K Tharpd, Steven E Bosinger, Jennifer C Felge. Neurotransmitter and metabolic effects of interferon-alpha in association with decreased striatal dopamine in a Non-Human primate model of Cytokine-Induced depression. Brain, behavior, and immunity. 2025-01-18. PMID:39826580. |
dopamine (but not serotonin or norepinephrine) was decreased in the nucleus accumbens (nacc) and putamen of ifn-a-treated animals (p < 0.05). |
2025-01-18 |
2025-01-23 |
Not clear |
| Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, Marina Belenky, Vasant R Marur, A John Rush, W Edward Craighead, Helen S Mayberg, Boadie W Dunlop, Bruce S Kristal, Rima Kaddurah-Daou. Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder. Journal of affective disorders. 2025-01-16. PMID:39818336. |
metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder. |
2025-01-16 |
2025-01-19 |
Not clear |
| Valeria V Kleandrova, M Natália D S Cordeiro, Alejandro Speck-Planch. Perturbation-theory machine learning for mood disorders: virtual design of dual inhibitors of NET and SERT proteins. BMC chemistry. vol 19. issue 1. 2025-01-03. PMID:39748442. |
here, we developed the first model perturbation-theory machine learning model based on a multiplayer perceptron network (ptml-mlp) for the simultaneous prediction and design of virtual dual-target inhibitors against two proteins associated with mood disorders, namely norepinephrine and serotonin transporters (net and sert, respectively). |
2025-01-03 |
2025-01-05 |
Not clear |
| Abdulsalam Mohammed Aleid, Faisal Alshehri, Naif Alasiri, Fatimah Alhomoud, Shouq Alsaegh, Mohammed Alrasheed, Salem Aljaddua, Ali Alasiri, Asma Boukhari, Abdulmonem Ali Alhussain, Bipin Chaurasia, Saud Nayef Aldanyow. Efficacy of Duloxetine for Postspine Surgery Pain: A Systematic Review and Meta-Analysis. Brain and behavior. vol 15. issue 1. 2024-12-31. PMID:39740780. |
duloxetine, a serotonin and norepinephrine reuptake inhibitor (snri), is used to treat various health conditions, including major depressive disorder, generalized anxiety disorder, fibromyalgia, and off-label for chemotherapy-induced pain. |
2024-12-31 |
2025-01-03 |
Not clear |
| Jose A Ontiveros-Sánchez de la Barquera, Luis Alberto De La Garza García, Silvia Viridiana Esquivel García, Guillermo Sánchez Torres, Grecia Alejandra Perez Jalom. Paradoxical Depressive Response to Intranasal Esketamine in Treatment-Resistant Depression: A Case Series. The American journal of case reports. vol 25. 2024-12-28. PMID:39731271. |
background esketamine is the only pharmacological agent with glutamatergic neuromodulator properties approved by the us food and drug administration and european medicines agency to enhance the effects of serotonin selective or serotonin and norepinephrine reuptake inhibitors. |
2024-12-28 |
2024-12-30 |
Not clear |
| Jingping Zheng, Zhenpo Zhang, Yankun Liang, Qimin Wu, Chufeng Din, Yuting Wang, Lin Ma, Ling S. Risk of congenital anomalies associated with psychotropic medications: a review of neonatal reports in the FDA adverse event reporting System (FAERS). Archives of women's mental health. 2024-12-22. PMID:39710735. |
this study investigates the potential association between commonly prescribed psychotropic medications, such as atypical antipsychotics (aas), selective serotonin reuptake inhibitors (ssris), and serotonin norepinephrine reuptake inhibitors (snris), and congenital anomalies in newborns. |
2024-12-22 |
2024-12-25 |
Not clear |
| Hugo R Arias, Deborah Rudin, Dino Luethi, Jan Valenta, Anna Leśniak, Zofia Czartoryska, Agnieszka Olejarz-Maciej, Agata Doroz-Płonka, Dina Manetti, Philippe De Deurwaerdère, Maria Novella Romanelli, Jadwiga Handzlik, Matthias E Liechti, Abdeslam Chagraou. The psychoplastogens ibogaminalog and ibogainalog induce antidepressant-like activity in naïve and depressed mice by mechanisms involving 5-HT Progress in neuro-psychopharmacology & biological psychiatry. 2024-12-11. PMID:39662723. |
to assess the contribution of serotonergic and/or norepinephrinergic neurotransmission, serotonin (5-ht) and norepinephrine (ne) levels were depleted. |
2024-12-11 |
2024-12-14 |
mouse |
| Arzoo Pannu, Ramesh K Goya. The Potential Role of Dopamine Pathways in the Pathophysiology of Depression: Current Advances and Future Aspects. CNS & neurological disorders drug targets. 2024-12-06. PMID:39639477. |
while the roles of serotonin and norepinephrine in depression have been extensively studied, the importance of dopaminergic pathways-essential for mood, cognition, motor control, and endocrine function-often gets overlooked. |
2024-12-06 |
2024-12-08 |
Not clear |
| L Batey, B Baumberger, H Khoshbouei, P Hashem. Lipopolysaccharide Effects on Neurotransmission: Understanding Implications for Depression. ACS chemical neuroscience. 2024-11-27. PMID:39601433. |
the levels of the monoamines dopamine, serotonin and norepinephrine are thought to be affected by both inflammation and depression. |
2024-11-27 |
2024-11-29 |
Not clear |
| Tatiana Sorkina, Tarique Bagalkot, Mary Hongying Cheng, Daryl A Guthrie, Amy Hauck Newman, Simon C Watkins, Alexander Sorki. Monoamine transporter ubiquitination and inward-open conformation synergistically maximize transporter endocytosis. Science advances. vol 10. issue 47. 2024-11-22. PMID:39576869. |
amphetamine strongly increases pkc-dependent endocytosis of norepinephrine transporter (net) but not of serotonin transporter (sert), correlating with a substantially weaker ubiquitination of sert compared to net. |
2024-11-22 |
2024-11-25 |
Not clear |
| Xiuqing Zhu, Yuexin Li, Huan Luo, Yunxia Zhang, Zhenqing Zhang, Jinglai L. Frontiers in pharmacology. vol 15. 2024-11-22. PMID:39575392. |
ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor, holds promise for major depressive disorder treatment. |
2024-11-22 |
2024-11-24 |
Not clear |
| Martina Rossetti, Stefano Stanca, Leona Bokulic Panichi, Paolo Bongioann. Brain metabolic profiling of schizophrenia: a path towards a better understanding of the neuropathogenesis of psychosis. Metabolic brain disease. vol 40. issue 1. 2024-11-21. PMID:39570439. |
indeed, the metabolic framework behind scz dopaminergic hypotheses, glutamate - gamma-amynobutyric acid dysregulation, norepinephrine and serotonin, calcium channel dysfunction is addressed together with the energetic impairment, involving glucose and lipids in scz etiopathogenesis, in order to highlight the multilevel pathways affected in this neuropsychiatric disorder. |
2024-11-21 |
2024-11-23 |
Not clear |